Guerbet S.A.

Guerbet is a French pharmaceutical group that develops, markets, and provides maintenance services for medical equipment and devices destined for diagnostic and interventional imaging. Co.'s portfolio comprises media solutions covering MRI, X-rays and products devoted to International Radiology and Theranostics and medical devices. Co. organizes its operation by product family covering Magnetic Resonance Imaging (MRI), X-rays (XR) and Interventional Radiology and Theranostics (IRT). The MRI family includes Dotarem® and Artirem®; Co.'s X-ray product family includes Xenetix®, Optiray®/Optiject®, Oxilan®, and Telebrix®; and the IRT product family has Lipiodol®, Bleu Patente V and Hexabrix®.
  • TickerGBT
  • ISINFR0000032526
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance

Analysts

Due to a more favourable environment, GUERBET slightly increases to Neutral

GUERBET (FR), a company active in the Pharmaceuticals industry, slightly increases its general evaluation. The independent financial analyst theScreener just confirmed the stock market behaviour of the title as moderately risky. At the fundamental level, theScreener confirms the rating of 1 out of 4 stars; given the more favourable environment, the title's overall rating is upgraded to Neutral even if it remains under pressure. As of the analysis date May 17, 2019, the closing price was EUR 49.55 and its target price was estimated at EUR 43.70.

Charles Pinel

Guerbet SA - Assemblée Générale des actionnaires du 24 mai 2019

Le conseil d'administration ne comprendra plus de dirigeant car le mandat d'administrateur du Directeur Général qui arrive à échéance n'est pas renouvelé. Il comprendra donc 10 membres contre 11 précédemment mais il est toujours composé d'une majorité de membres non libres de conflits d'intérêts potentiels, ce qui ne permet pas d'approuver le renouvellement d'un membre de la famille Guerbet, d'autant plus que cette famille est en sur-représentation avec 60% des sièges du conseil pour 53% du capital (résolution 13). Comme chaque année, les politiques de rémunération des dirigeants mandataires ...

Aurelien Sivignon ...
  • Baptiste Lebacq
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Fatma Agnès Hamdani
  • Fehmi Ben Naamane
  • Geoffroy Michalet
  • Hana Maalej
  • Hela Zarrouk
  • Jean-François Granjon
  • Jeremy Garnier
  • Johanna Jourdain
  • Louis Boujard
  • Michael Foundoukidis
  • Nicolas Thorez
  • Philippe Ourpatian
  • Stephane Houri

ODDO BHF Small & MIDCAP MORNING NEWS - 04/23/2019

...

Aurelien Sivignon ...
  • Baptiste Lebacq
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Fatma Agnès Hamdani
  • Fehmi Ben Naamane
  • Geoffroy Michalet
  • Hana Maalej
  • Hela Zarrouk
  • Jean-François Granjon
  • Jeremy Garnier
  • Johanna Jourdain
  • Louis Boujard
  • Michael Foundoukidis
  • Nicolas Thorez
  • Philippe Ourpatian
  • Stephane Houri

ODDO BHF Small & MIDCAP MORNING NEWS - 23/04/2019

...

Christophe-Raphaël Ganet

Guerbet : Somewhat strong Q1 2019 sales, lifted by a positive base effect

>Q1 (+7.7%) a shade above our expectations - Q1 sales stood at € 197.3m, up 7.7% and +6.7%.In Europe, sales saw double-digit growth (+11.6%) thanks in particular to solid sales in Germany and Turkey and a favourable base effect. In the US, sales continued to grow in the absence of the launch of a generic version of Dotarem®. Conversely, sales remained stable in Asia, with a satisfactory take-off in sales in Japan (subsidiary since 2018 vs. distributor) but a...

Aurelien Sivignon ...
  • Baptiste Lebacq
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Fatma Agnès Hamdani
  • Fehmi Ben Naamane
  • Geoffroy Michalet
  • Hana Maalej
  • Hela Zarrouk
  • Jean-François Granjon
  • Jeremy Garnier
  • Johanna Jourdain
  • Louis Boujard
  • Michael Foundoukidis
  • Nicolas Thorez
  • Philippe Ourpatian
  • Stephane Houri

ODDO BHF Small & MIDCAP MORNING NEWS - 04/23/2019

...

Aurelien Sivignon ...
  • Baptiste Lebacq
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Fatma Agnès Hamdani
  • Fehmi Ben Naamane
  • Geoffroy Michalet
  • Hana Maalej
  • Hela Zarrouk
  • Jean-François Granjon
  • Jeremy Garnier
  • Johanna Jourdain
  • Louis Boujard
  • Michael Foundoukidis
  • Nicolas Thorez
  • Philippe Ourpatian
  • Stephane Houri

ODDO BHF Small & MIDCAP MORNING NEWS - 23/04/2019

...

Christophe-Raphaël Ganet

Guerbet : Somewhat strong Q1 2019 sales, lifted by a positive base effect

>Q1 (+7.7%) a shade above our expectations - Q1 sales stood at € 197.3m, up 7.7% and +6.7%.In Europe, sales saw double-digit growth (+11.6%) thanks in particular to solid sales in Germany and Turkey and a favourable base effect. In the US, sales continued to grow in the absence of the launch of a generic version of Dotarem®. Conversely, sales remained stable in Asia, with a satisfactory take-off in sales in Japan (subsidiary since 2018 vs. distributor) but a...

Pierre Vaurice

GUERBET - CA T1 2019 (+) Bon démarrage 2019

GUERBET - CA T1 2019 (+) Bon démarrage 2019

Christophe-Raphaël Ganet

Guerbet : Feedback from analysts’ meeting: Clariscan still a cause for concern in 2019

>On track for its Gear 2023 plan but a number of uncertainties - Over and above the presentation of its 2018 figures yesterday, management focused on its exposure to i/ hopes on the successor for Dotarem®, gadopiclenol (strong relaxant, phase III protocol apparently resoundingly validated by the EMEA and FDA, the only molecule in R&D in MRI); ii/ the launch of the commercialisation of Accurate products (catheters) already approved and sold in the US (CE marking antici...

Amine Daly ...
  • Aurelien Sivignon
  • Charles Lepetitpas
  • Christophe-Raphaël Ganet
  • Jeremy Garnier
  • Nicolas Thorez
  • Stephane Houri

ODDO BHF Small & MIDCAP MORNING NEWS - 03/28/2019

...

Amine Daly ...
  • Aurelien Sivignon
  • Charles Lepetitpas
  • Christophe-Raphaël Ganet
  • Jeremy Garnier
  • Nicolas Thorez
  • Stephane Houri

ODDO BHF Small & MIDCAP MORNING NEWS - 28/03/2019

...

Alain William ...
  • Anis Zgaya
  • Aurelien Sivignon
  • Christophe-Raphaël Ganet
  • Fatma Agnès Hamdani
  • Hana Maalej
  • Jean-François Granjon
  • Jeremy Garnier
  • Khaled Ben Amor
  • Nicolas Thorez

ODDO BHF Small & MIDCAP MORNING NEWS - 03/27/2019

...

Alain William ...
  • Anis Zgaya
  • Aurelien Sivignon
  • Christophe-Raphaël Ganet
  • Fatma Agnès Hamdani
  • Hana Maalej
  • Jean-François Granjon
  • Jeremy Garnier
  • Khaled Ben Amor
  • Nicolas Thorez

ODDO BHF Small & MIDCAP MORNING NEWS - 27/03/2019

...

Aurelien Sivignon ...
  • Charles Lepetitpas
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Jean-François Granjon
  • Jeremy Garnier
  • Jerôme Bodin
  • Michael Foundoukidis
  • Nicolas David
  • Salma Bouraoui
  • Sven Edelfelt
  • Team Pharma
  • Virginie Rousseau

ODDO BHF Small & MIDCAP MORNING NEWS - 10/26/2018 Date Performance since listing Date Performance since listing

...

Due to a more favourable environment, GUERBET slightly increases to Neutral

GUERBET (FR), a company active in the Pharmaceuticals industry, slightly increases its general evaluation. The independent financial analyst theScreener just confirmed the stock market behaviour of the title as moderately risky. At the fundamental level, theScreener confirms the rating of 1 out of 4 stars; given the more favourable environment, the title's overall rating is upgraded to Neutral even if it remains under pressure. As of the analysis date May 17, 2019, the closing price was EUR 49.55 and its target price was estimated at EUR 43.70.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Charles Pinel

Guerbet SA - Assemblée Générale des actionnaires du 24 mai 2019

Le conseil d'administration ne comprendra plus de dirigeant car le mandat d'administrateur du Directeur Général qui arrive à échéance n'est pas renouvelé. Il comprendra donc 10 membres contre 11 précédemment mais il est toujours composé d'une majorité de membres non libres de conflits d'intérêts potentiels, ce qui ne permet pas d'approuver le renouvellement d'un membre de la famille Guerbet, d'autant plus que cette famille est en sur-représentation avec 60% des sièges du conseil pour 53% du capital (résolution 13). Comme chaque année, les politiques de rémunération des dirigeants mandataires ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch